Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting

Francesca Lombardi; Simone Belmonti; Davide Moschese; Massimiliano Fabbiani; Alberto Borghetti; Arturo Ciccullo; Elena Visconti; Simona Di Giambenedetto

doi:10.1080/25787489.2022.2080625

Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting

Francesca Lombardi^*
, Simone Belmonti
, Davide Moschese
, Massimiliano Fabbiani
, Alberto Borghetti
, Arturo Ciccullo
, Elena Visconti
, Simona Di Giambenedetto

^*Corresponding author

Azienda Ospedaliera Universitaria Senese
Gemelli Molise

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	28-36
Number of pages	9
Journal	HIV Research and Clinical Practice
Volume	23
Issue number	1
DOIs	https://doi.org/10.1080/25787489.2022.2080625
Publication status	Published - 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Infectious Diseases
Pharmacology (medical)

Keywords

3-Ring
Anti-HIV Agents
Biomarkers
HIV
HIV Infections
HIV-1
Heterocyclic Compounds
Humans
Inflammation
Interleukin-6
Lamivudine
Longitudinal Studies
Oxazines
Piperazines
Pyridones
Viral Load
dolutegravir
dual therapy
inflammation
inflammatory biomarkers
lamivudine

Access to Document

10.1080/25787489.2022.2080625

Cite this

Lombardi, F., Belmonti, S., Moschese, D., Fabbiani, M., Borghetti, A., Ciccullo, A., Visconti, E., & Di Giambenedetto, S. (2022). Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting. HIV Research and Clinical Practice, 23(1), 28-36. https://doi.org/10.1080/25787489.2022.2080625

@article{49fc1c96bbb14af4be7a7fff5f0606fe,

title = "Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting",

keywords = "3-Ring, Anti-HIV Agents, Biomarkers, HIV, HIV Infections, HIV-1, Heterocyclic Compounds, Humans, Inflammation, Interleukin-6, Lamivudine, Longitudinal Studies, Oxazines, Piperazines, Pyridones, Viral Load, dolutegravir, dual therapy, inflammation, inflammatory biomarkers, lamivudine, 3-Ring, Anti-HIV Agents, Biomarkers, HIV, HIV Infections, HIV-1, Heterocyclic Compounds, Humans, Inflammation, Interleukin-6, Lamivudine, Longitudinal Studies, Oxazines, Piperazines, Pyridones, Viral Load, dolutegravir, dual therapy, inflammation, inflammatory biomarkers, lamivudine",

author = "Francesca Lombardi and Simone Belmonti and Davide Moschese and Massimiliano Fabbiani and Alberto Borghetti and Arturo Ciccullo and Elena Visconti and \{Di Giambenedetto\}, Simona",

year = "2022",

doi = "10.1080/25787489.2022.2080625",

language = "English",

volume = "23",

pages = "28--36",

journal = "HIV Research and Clinical Practice",

issn = "2578-7489",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

Lombardi, F, Belmonti, S, Moschese, D, Fabbiani, M, Borghetti, A, Ciccullo, A, Visconti, E & Di Giambenedetto, S 2022, 'Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting', HIV Research and Clinical Practice, vol. 23, no. 1, pp. 28-36. https://doi.org/10.1080/25787489.2022.2080625

Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting. / Lombardi, Francesca; Belmonti, Simone; Moschese, Davide et al.
In: HIV Research and Clinical Practice, Vol. 23, No. 1, 2022, p. 28-36.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting

AU - Lombardi, Francesca

AU - Belmonti, Simone

AU - Moschese, Davide

AU - Fabbiani, Massimiliano

AU - Borghetti, Alberto

AU - Ciccullo, Arturo

AU - Visconti, Elena

AU - Di Giambenedetto, Simona

PY - 2022

Y1 - 2022

KW - 3-Ring

KW - Anti-HIV Agents

KW - Biomarkers

KW - HIV

KW - HIV Infections

KW - HIV-1

KW - Heterocyclic Compounds

KW - Humans

KW - Inflammation

KW - Interleukin-6

KW - Lamivudine

KW - Longitudinal Studies

KW - Oxazines

KW - Piperazines

KW - Pyridones

KW - Viral Load

KW - dolutegravir

KW - dual therapy

KW - inflammation

KW - inflammatory biomarkers

KW - lamivudine

KW - 3-Ring

KW - Anti-HIV Agents

KW - Biomarkers

KW - HIV

KW - HIV Infections

KW - HIV-1

KW - Heterocyclic Compounds

KW - Humans

KW - Inflammation

KW - Interleukin-6

KW - Lamivudine

KW - Longitudinal Studies

KW - Oxazines

KW - Piperazines

KW - Pyridones

KW - Viral Load

KW - dolutegravir

KW - dual therapy

KW - inflammation

KW - inflammatory biomarkers

KW - lamivudine

UR - https://publicatt.unicatt.it/handle/10807/214194

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85133102196&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85133102196&origin=inward

U2 - 10.1080/25787489.2022.2080625

DO - 10.1080/25787489.2022.2080625

M3 - Article

SN - 2578-7489

VL - 23

SP - 28

EP - 36

JO - HIV Research and Clinical Practice

JF - HIV Research and Clinical Practice

IS - 1

ER -

Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting

UN SDGs

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Cite this